| Placebo | Strontium ranelate | p Value* | |
| N = 185 | N = 168 | ||
| Age, years | 60 (3.4) | 60 (3.6) | NS |
| Years since menopause | 13.4 (6.1) | 13.5 (6.0) | NS |
| BMI (kg/m2) | 26.1 | 26.7 | NS |
| ⩾1 Prevalent vertebral fracture (%) | 153 (82.7) | 131 (78.0) | NS |
| Previous non-vertebral fracture (%) | 50 (27.0) | 31 (18.5) | NS |
| Bone mineral density | |||
| Lumbar spine T score | −3.7 (1.0) | −3.5 (1.2) | NS |
| Femoral neck T score | −2.5 (0.8) | −2.5 (0.8) | |
| Femoral neck T score (NHANES III reference) | −1.92 | −1.92 |
Data are presented as mean values (SD).
*Wilcoxon test between the two groups of treatment.
BMI, body mass index; NHANES, National Health and Nutrition Examination Survey III.